OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Abstract:
Over the last decade, our research provides strong evidence that the drivers of minimal residual disease (MRD) survival are different from those that drive bulk ovarian cancer. Therefore, eliminating minimal residual disease at the end of traditional treatment requires rationalised therapeutics that specifically target MRD drivers. In this talk I will discuss our recent work in characterising MRD in ovarian cancer and our ongoing work to develop therapeutics to eliminate it.
